Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss - BioPharma Dive
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss BioPharma Dive
Eli Lilly Company News
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis - Fox 59
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis Fox 59
Lilly celebrates 150 years on precipice of new era - Axios
Lilly celebrates 150 years on precipice of new era Axios
Eli Lilly on big upswing in research as Indy company marks 150 years - IndyStar
Eli Lilly on big upswing in research as Indy company marks 150 years IndyStar
Eli Lilly launches Alzheimer's drug Donanemab in India - Reuters
Eli Lilly launches Alzheimer's drug Donanemab in India Reuters
Is Eli Lilly and Company (LLY) A Good Stock To Buy Now? - Yahoo Finance
Is Eli Lilly and Company (LLY) A Good Stock To Buy Now? Yahoo Finance
Is It Too Late To Consider Eli Lilly (LLY) After Its Strong Share Price Rally? - simplywall.st
Is It Too Late To Consider Eli Lilly (LLY) After Its Strong Share Price Rally? simplywall.st
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries - PR Newswire
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries PR Newswire
AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years - WISH-TV
AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years WISH-TV
Why is Eli Lilly stock rallying today? - Investing.com
Why is Eli Lilly stock rallying today? Investing.com
Jim Cramer Believes “It Is a Bull Market for Eli Lilly” - Insider Monkey
Jim Cramer Believes “It Is a Bull Market for Eli Lilly” Insider Monkey
Eli Lilly Expands Indiana Pharma Manufacturing With $4.5 Billion Investment - Construction Owners Club
Eli Lilly Expands Indiana Pharma Manufacturing With $4.5 Billion Investment Construction Owners Club
Eli Lilly Just Announced Fantastic News for Shareholders - The Motley Fool
Eli Lilly Just Announced Fantastic News for Shareholders The Motley Fool
Eli Lilly (LLY) Stock Trades Up, Here Is Why - TradingView
Eli Lilly (LLY) Stock Trades Up, Here Is Why TradingView
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - investor.lilly.com
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines investor.lilly.com
Byron Donalds trades in Chipotle, Eli Lilly, Intuit, and Marvell Technology stocks - Investing.com
Byron Donalds trades in Chipotle, Eli Lilly, Intuit, and Marvell Technology stocks Investing.com
Eli Lilly Marks 150 Years With Food Security Drive And Investor Angles - simplywall.st
Eli Lilly Marks 150 Years With Food Security Drive And Investor Angles simplywall.st
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - investor.lilly.com
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions investor.lilly.com
Eli Lilly Ulcerative Colitis Data Highlights Omvoh Durability And Valuation Upside - simplywall.st
Eli Lilly Ulcerative Colitis Data Highlights Omvoh Durability And Valuation Upside simplywall.st
Eli Lilly launches Alzheimer's drug Donanemab in India - Yahoo News Singapore
Eli Lilly launches Alzheimer's drug Donanemab in India Yahoo News Singapore
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - investor.lilly.com
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes investor.lilly.com
Eli Lilly & Co. stock (US5324571083): Q1 2026 earnings beat and guidance hike keep obesity boom stor - AD HOC NEWS
Eli Lilly & Co. stock (US5324571083): Q1 2026 earnings beat and guidance hike keep obesity boom stor AD HOC NEWS
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket - CNBC
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket CNBC
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - investor.lilly.com
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance investor.lilly.com
Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company - investor.lilly.com
Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company investor.lilly.com
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility - investor.lilly.com
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility investor.lilly.com
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans - investor.lilly.com
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans investor.lilly.com
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma - news.financial
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma news.financial
Eli Lilly Just Delivered Fantastic News to Investors - Yahoo Finance
Eli Lilly Just Delivered Fantastic News to Investors Yahoo Finance
Why Eli Lilly Stock Slumped Today - Yahoo Finance
Why Eli Lilly Stock Slumped Today Yahoo Finance
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings - Investopedia
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings Investopedia
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company - investor.lilly.com
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company investor.lilly.com
Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Yahoo Finance
Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment Yahoo Finance
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - investor.lilly.com
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 investor.lilly.com
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company - investor.lilly.com
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company investor.lilly.com
Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why - Yahoo Finance
Eli Lilly and Company (LLY) Gets Downgraded to Reduce From Hold by HSBC – Here’s Why Yahoo Finance
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - investor.lilly.com
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen investor.lilly.com
Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company - investor.lilly.com
Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company investor.lilly.com
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health - investor.lilly.com
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health investor.lilly.com
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company - investor.lilly.com
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company investor.lilly.com